NCT05408728
Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome
Enrolling by Invitation
Not specifiedAges 18+ObservationalMayo ClinicInvestigator-initiated
~52 participants
Updated 2025-09-10 on ClinicalTrials.gov
What's tested:Endoscopic biopsy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of obese patients with altered dietary sugar hyper-absorptive phenotype after bariatric surgery
Measured over 18 months
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Dilhana Badurdeen, MBBS, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Adults unable to consent, including non-English speakers.
Pregnant women because endoscopy is a risk factor. All patients of childbearing age undergo history as well as urine pregnancy test as a standard of care prior to undergoing endoscopy as the procedure is performed under anesthesia.
Prisoners.
Subjects with preexisting conditions (e.g., bleeding at the time of the procedure, suspected perforation during the standard-of-care procedure) will be excluded from the study at the time of the endoscopy.
Have a contraindication to endoscopy.
A history of surgery on the stomach or small intestine.
Type 1 diabetes (clinical diagnosis and/or positive glutamic acid decarboxylase antibodies).
Using weight loss medications.
Active malignancy within the last 5 years.
What this trial measures
- Number of obese patients with altered dietary sugar hyper-absorptive phenotype after bariatric surgery18 months